Cover page

Title:

Adherence and persistence to basal insulin among people with type 2 diabetes in Europe - a systematic literature review and meta-analysis

Authors:

Esteban J Gimeno¹, Mette Bøgelund², Sara Larsen³, Anna Okkels², Signe B Reitzel², Hongye Ren³, Domingo Orozco-Beltran⁴

Affiliations:

¹Faculty of Medicine, Universidad Europea deMadrid, Madrid, Spain ²EY Economics, Dirch Passers Allé 36, 2000 Frederiksberg, Denmark, ³Novo Nordisk, Region North West Europe, Kay Fiskers Plads 10, 7th floor, 2300 Copenhagen S, Denmark, ⁴Cátedra de Medicina de Familia, Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, España

Corresponding author:

Hongye Ren

Novo Nordisk, Region North West Europe, Kay Fiskers Plads 10, 7th floor, 2300 Copenhagen S, Denmark HYRN@novonordisk.com

+45 3075 2419

Supplementary material

Figure S1: Forest plot for non-persistence within 6 months of basal insulin treatment




Figure S2: Forest plot for non-persistence within 6 months of basal insulin treatment (register-based data only)




Figure S3: Forest plot for non-persistence within 6 months of basal insulin treatment (based on self-reported data only)




Figure S4: Forest plot for non-persistence within 12 months of basal insulin treatment

Study	Events	Total		Weight, F-T, Random, 95% CI	
Eliasson et al. 2020	278	1760	+ ■+	14.25%	0.158 [0.141, 0.175]
Quinzler et al. 2012 (Glargine)	28520	61070	•	14.34%	0.467 [0.463, 0.471]
Roussel et al. 2016	344	1199		14.21%	0.287 [0.262, 0.313]
Roussel et al. 2020 (Detemir)	10020	25830		14.34%	0.388 [0.382, 0.394]
Roussel et al. 2020 (Glargine-100)	48735	134127		14.35%	0.363 [0.361, 0.366]
Roussel et al. 2020 (Glargine-300)	3014	21306		14.34%	0.141 [0.137, 0.146]
Sicras et al. 2013	412	935	⊢	14.17%	0.441 [0.409, 0.473]
Total (95% CI)	91323	246227			0.313 [0.217, 0.418]
Heterogeneity: $\tau^2 = 0.02$, $\chi^2 = 9036.94$, df	$=6 (P < 0.0001) I^2 =$	=100			
			0.1 0.2 0.3 0.4 0.5		
			Proportion		

Figure S5: Forest plot for non-persistence within 12 months of basal insuling treatment (excluding NPH)




Figure S6: Forest plot for non-persistence within 18 months of basal insulin treatment




Figure S7: Forest plot for non-persistence within 6 months of basal insulin treatment (excluding Sicras et al. 2013)




Figure S8: Forest plot for non-persistence within 12 months of basal insulin treatment (excluding Sicras et al. 2013)




Figure S9: Forest plot for adherence of basal insulin treatment (MPR >80%)




Figure \$10: Forest plot for adherence of basal insulin treatment measured by MPR >80% (excluding Sicras et al. 2013)

Study	Events	Total	Weight, F-T, Random, 95% CI		
Esposti et al. 2019 (Insulin only)	191	466	-■-	33.18%	0.410 [0.366, 0.455]
Esposti et al. 2019 (OGLD)	984	1590		33.95%	0.619 [0.595, 0.643]
Esposti et al. 2019 (DPP-4 I)	230	357		32.86%	0.644 [0.594, 0.693]
Total (95% CI)	1405	2413			0.559 [0.413, 0.699]
Heterogeneity: $\tau^2 = 0.02$, $\chi^2 = 70.47$, df=	2 (P< 0.0001) $I^2 = 9$	7.5			
			0.3 0.5 0.7		
			Proportion		